SLC16A1 and diffuse large B-cell lymphoma: For instance, SLC16A1 is significantly upregulated in diffuse large B-cell lymphoma (DLBCL) and downregulated in AML, while the opposite is true for SLC16A3. Moreover, the expression of SLC16A1 and SLC16A3 is negatively correlated on a pan-cancer and AML-specific level (Fig. 7c–e), indicating that in a subset of cancer patients the expression pattern of these MCTs is divergent and suggestive of eligibility for AZD3965 therapy or other inhibitors specific for one of the two transporters.